Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis: A Prospective, Multi-Center, Real-World Study

NCT06962020 is registered in ClinicalTrials.gov with Xijing Hospital of Digestive Diseases as lead sponsor.

NCT NCT06962020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06962020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis: A Prospective, Multi-Center, Real-World Study
Lead sponsor
Xijing Hospital of Digestive Diseases
Phase
Observational
Overall status
Recruiting
Start date
April 30, 2025
Completion date
November 20, 2025
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)